Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BI gets diabetes, obesity candidates from Zealand Pharma

Executive Summary

Danish biotech Zealand Pharma AS has licensed Boehringer Ingelheim GMBH exclusive worldwide rights to develop and sell glucagon/glucagon-like peptide 1 (GLP-1) agonists for Type II diabetes and obesity.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information
    • Co-Promotion

Related Companies

UsernamePublicRestriction

Register